Abstract Insulin-like growth factor (IGF)-I is markedly induced after balloon injury in the rat aorta, where it may serve to mediate vascular repair. Because the bioavailability of IGF-I is modulated by IGF-binding proteins (IGFBPs), we examined the regulation of IGFBPs by IGFs in primary cultures of rat aortic smooth muscle cells (SMCs). Serumdeprived SMC-conditioned medium contains IGFBPs of 38 to 45 kD (only in confluent cultures), 30 kD (possibly IGFBP-2), 28 kD, and 24 kD (IGFBP-4), the latter being the most abundant. IGF-I and IGF-II but not insulin evoked a marked decrease of IGFBP-4 as early as 4 hours after treatment.
IGFBP-4 mRNA abundance, however, was entirely unaffected by IGF-I for up to 48 hours. IGF-I analogues with high affinity for the IGF-I receptor and weak affinity for IGFBP paradoxically evoked a small increase in IGFBP-4, probably through a general increase in protein synthesis. IGF-I only minimally decreased IGFBP-4 content in medium of sparse cultures, whereas it completely abolished IGFBP-4 content in conditioned medium of superconfluent SMCs. IGF-I also evoked a concentration-dependent increase in the abundance of IGFBP-3 in confluent, but not sparse, SMCs without affecting IGFBP-3 mRNA. Addition of IGF-I to cell-free medium V urascular smooth muscle cells (SMCs) provide structure and elasticity to the vessel wall.
Under normal conditions, the replication rate of arterial SMCs is <0.2%. When subjected to pathological stimuli, such as occur in the formation of the atherosclerotic lesion, or after intravascular injury, SMCs regain the ability to proliferate.1-5 It has become increasingly apparent that SMC migration and proliferation is controlled to a great extent in a paracrine fashion.6,7 Indeed, SMCs can autoregulate their growth characteristics both in vivo and in vitro by elaborating growth factors, modulating the population of growth factor receptors in the plasma membrane, and influencing the composition of the extracellular matrix that surrounds them. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Insulin-like growth factor (IGF)-I and IGF-II are peptide hormones that share structural homology with proinsulin and relaxin.18 IGF-I is thought to be the mediator of most of the growth-promoting effects of growth hormone. In addition to its endocrine effects, IGF-I is also expressed in multiple tissues, where it is believed to be involved in the paracrine control of cell proliferation. IGF-I gene expression is markedly induced in the rat aorta after balloon injury, an event associated with a reciprocal downregulation of the IGF-I receptor.12'13 It is well recognized that IGF-I is a mitogen for SMCs. 19 These data suggest that IGF-I exerts its effects within the vessel wall, probably by stimulating SMC growth. Perhaps more significant, there is a cooperative effect between IGF-I and other powerful mesenchymal cell mitogens such as platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in the promotion of SMC proliferation.21 '22 A novel class of carrier proteins has been identified; these proteins bind to IGFs with high affinity and appear to modulate IGF action (IGF-binding proteins [IGFBPs] ). 23 The six IGFBPs characterized so far share considerable structural homology and are found in body fluids and condi-tioned media from a variety of cell types. The expression of IGFBPs tends to be tissue and cell specific and is developmentally regulated. We24 and others25 have reported that rat aortic SMCs elaborate IGFBPs of 37 to 42, 30, and 24 kD. The 24-kD IGFBP is the most abundant form in subconfluent SMC cultures; it comigrates, is probably identical to IGFBP-4, and is induced by PDGF. 25 By stimulating the expression of the inhibitory protein IGFBP-4, PDGF may set in motion mechanisms to limit the extent of the mitogenic response. Recently, specific proteolytic activities have been identified in the conditioned medium of fibroblasts of different species that cleave IGFBP-4 after exposure to IGF-I. [26] [27] [28] In the present study, we examined the effects of IGFs on the production of their carrier proteins in SMCs, with a focus on IGFBP-4. We demonstrate that IGF-I regulates the abundance of IGFBP-4 by evoking its proteolysis by cation-dependent protease(s), thus releasing free structurally intact IGF-I. Furthermore, both biosynthesis and the IGF-I-dependent degradation of IGFBP-4 are highly sensitive to cell density. These data predict that an intricate set of events control access of IGF-I to its cognate receptor in vascular SMCs.
Materials and Methods Cell Culture
SMCs were isolated from rat thoracic aorta and cultured by a modification of the method of Chamley-Campbell et al,29 with minor modifications.30,31 Briefly, 90-day-old male Sprague-Dawley rats (Harlan Sprague Dawley, Inc, Indianapolis, Ind) weighing 300 g were asphyxiated with CO2. A section of the aorta, from the aortic arch to the level of the renal arteries, was aseptically excised and placed in cold Hanks' balanced salt solution (HBSS, GIBCO, Grand Island, NY). Adhering fat and connective tissue from the adventitia were stripped off by blunt dissection. Three or four vessels were extensively washed with fresh HBSS before being longitudinally opened. The opened aortas were dissociated in an enzymatic solution containing 0.1% collagenase (type CLS 2, 130 U/mg, Worthington Biochemical Corp, Freehold, NJ), 0.05% elastase (Sigma Chemical Co, St Louis, Mo), 100 U/mL penicillin, and 100 ,g/mL streptomycin (Irvine Scientific, Santa Ana, Calif) for 15 to 20 minutes at 37°C in 95% air/5% CO2. The rest of the external connective tissue was then carefully removed under magnification, and the endothelial layer was scraped with a forceps. After dissection, aortas were placed in a fresh enzyme solution, minced into 1-to 2-mm pieces, and incubated in the above-mentioned conditions for an additional 1.5 to 2.0 hours. The suspension was triturated at 30-minute intervals. After the enzymatic disaggregation, the suspension was filtered through a nylon mesh and pelleted by centrifugation at llOg for 10 minutes. Cells were resuspended with 8 mL of Dulbecco's modified Eagle's medium (DMEM, Irvine Scientific). An aliquot of 100 ,uL was withdrawn, and cell viability was evaluated by trypan blue dye exclusion before inactivating the enzymes by addition of 1.98 mL fetal calf serum (FCS, Hyclone Laboratories, Logan, Utah). Flasks (75 cm2, Costar Corp, Cambridge, Mass) were inoculated at a density of 2x 104 viable cells per square centimeter.
After :2 weeks, the cells from the primary culture were harvested with a solution of trypsin (0.01%, Sigma) and collagenase (0.02%, Sigma) and plated at 2x104 cells per square centimeter. Subcultures were grown in DMEM supplemented with 10% FCS, 200 mmol/L L-glutamine (Irvine Scientific), and antibiotics, with media changes three times weekly.
Cells were used between the third and seventh passage. After being rinsed twice, cells were incubated with serum-free DMEM (Irvine Scientific) supplemented with L-glutamine (Irvine Scientific), 5 ug/mL transferrin, 0. 
Immunoprecipitation/Western-Ligand Blotting
To confirm the identity of the 24-kD IGFBP, 300 ,L of an 8x concentrate of SMC-conditioned medium was incubated with 20 ,L of one of the following polyclonal antibodies: ar4, ah4 (to rat and human IGFBP-4, respectively; kind gifts from P. Fielder and R. Rosenfeld, Stanford University), anti-IGFBP-4 (human) (UBI, Lake Placid, NY), or nonimmune rabbit serum in the presence of 30 ,L of protein A (Repligen, Cambridge, Mass) for 16 hours at 4°C, with shaking. After centrifugation, the pellets were washed, dried, and resuspended in 1 x sample buffer, without /3-mercaptoethanol, and Western-ligand-blotted as described.
Protease Assays SMC-conditioned media were collected and immediately stored at -20°C until assayed. To study degradation of IGFBP-4, the conditioned medium was exposed to varying temperatures or incubated with the various protease inhibitors for the indicated times before Western-ligand blotting. To further study proteolysis, 80000 cpm of purified human i2I-IGFBP-4 (100 gCi/lg) was incubated with 50 gL of an 8 x concentrate of SMC-conditioned medium for 6 hours in the presence or absence of 50 ng/mL IGF-I, des (1-3) IGF-I, or R3 IGF-I (Gro-Pep, Adelaide, Australia), with or without the indicated concentrations of protease inhibitors. Unreduced samples were fractionated by SDS-polyacrylamide gel electrophoresis using a 10% to 20% linear gradient.
RNA Extraction
RNA was extracted from cells in culture by the method of Chirgwin et al. 33 Briefly, the medium was removed from each flask and stored at -70°C for further use. The cells were washed twice at 4°C with sterile 0.01 mol/L phosphate-buffered saline, pH 7.5. Five milliliters of a lysis solution containing 4 mol/L guanidine isothiocyanate, 3 mol/L sodium acetate (pH 6.0), 0.5% sodium N-lauroylsarcosine, and 0.83% f-mercaptoethanol was added to each culture flask, and the cells were scraped with a rubber policeman. The suspension was homogenized with a sonicator for 30 seconds before being layered onto 4 mL of 5.7 mol/L cesium chloride and centrifuged for 18 to 20 hours at 170 000g at 20°C. The supernatant was carefully removed, and the clear RNA pellet was resuspended with 0.3 mol/L sodium acetate by repeated pipetting. The solubilized RNA was precipitated overnight with 2.5 vol of ethanol at -20°C. The RNA was then pelleted, washed with 80% ethanol, dried, and resuspended in 10 mmol/L Tris-HCl (pH 7.5) and 1 mmol/L EDTA. UV spectrophotometry at 260 mmol/L was used for quantification of total RNA. The integrity and accuracy of the RNA quantification were confirmed by submitting 5.0-,ug aliquots of each sample to 1% agarose/ formaldehyde gel electrophoresis and ethidium bromide staining. Only undegraded samples with intact 28S/18S ribosomal RNA and optical absorbance A2,280 ratios of >1.9 were processed.
Northern Blots
For Northern blot analysis, gel electrophoresis of 20 gg total RNA was performed on 1% agarose gels containing 2.2 mol/L formaldehyde, as previously described. 34 The filters were hybridized in a buffer containing 50% formamide, 5 x SSPE (43.8 g/L NaCl, 6 .9 g/L NaH2PO4* H2O, and 1.85 g/L EDTA), 5 x Denhardt's solution (1 g/L polyvinylpyrrolidone, 1 g/L BSA, and 1 g/L Ficoll 400), 0.1% SDS, and 200 ,ug/mL salmon sperm DNA for 48 hours at 42°C with 32P-labeled DNA probes. Probes were labeled with [a-32PIdCTP using the random-primer technique35 following the manufacturer's protocol (Stratagene, La Jolla, Calif). The following rat probes were used: IGFBP-1, pRDBP, and EcoRI-EcoRI fragment36; IGFBP-2, pRBP2-501, and EcoRI-HindIll fragment37; IGFBP-3, pRFI507, andApa I-Rso I fragment38; IGFBP-4, pRBP4-501, and Sma 1-HindIII fragment39; and cyclophylin, pCD15.8.1, and BamHI fragment. 40 Chromatography of 125I-IGF-I in SMC-Conditioned Medium As will be shown below, confluent SMCs release a protease that cleaves IGFBP-4 only after it is bound to IGFs. To determine how this proteolytic activity affects IGF-I itself, 0.1 ,Ci 125I-IGF-I was incubated with 50 4L cell-free conditioned medium from confluently plated SMCs for up to 48 hours. At the indicated times, the integrity of the labeled IGF-I was examined by gel permeation chromatography and reversephase high-performance liquid chromatography (HPLC). Gel permeation was performed in the presence or absence of 10% ,3-mercaptoethanol, using a Spherogel TSK 3000 PW column. The mobile phase was 0.3 mol/L triethylamine/P04H3, pH 7.0, and 20% propanol. For reverse-phase HPLC, the mixture was made up to 500 ,Lwith 1% trifluoroacetic acid (phase A). The mobile phase was a gradient of 85% to 100% methanol in 30 minutes (phase B), at a rate of 1 mL/min. Samples were injected into a Beckman HPLC apparatus consisting of 110B solvent delivery modules, a System Gold programmable detector controlled by a 406 analog interface, and a 25-cm Vydac C18 column. One-milliliter fractions were collected and counted.
Results As shown in Fig 1, IGF-I evoked a rapid concentration-dependent decrease in the abundance of the 24-kD protein, previously shown to comigrate with IGFBP-4.25 In contrast, there was a modest increase in the abundance of the 28-and 30-kD IGFBPs at 24 hours. Interestingly, the rapid inhibition of IGFBP-4 by IGF-I occurs in the absence of changes in the steady-state levels of the 2.6-kb IGFBP-4 mRNA (Fig 1B) .
To confirm the identity of the 24-kD IGFBP in SMC-conditioned medium, immunoprecipitation/Western-ligand blotting experiments were performed using three different polyclonal antibodies to IGFBP-4 ( Fig  2) . As shown in panel A, the two antibodies directed against human IGFBP-4 recognized the corresponding purified protein (lanes 4 and 5), revealing a band that comigrated with human IGFBP-4, which had not been subjected to immunoprecipitation. Panel B shows an almost identical immunoprecipitation/Western-ligand blot with a concentrate of rat SMC-conditioned medium, which in addition was also faintly recognized by the low-affinity rat-specific IGFBP-4 antiserum ar-4.
A comparison of the effects of the major members of the insulin/IGF family on IGFBP in SMCs is shown in On repeated experimentation, a degree of variability in basal and IGF-I-dependent changes in IGFBP content of SMC-conditioned medium was observed, an effect that appeared to be dependent on cell density. The influence of cell confluence on IGF-I regulation of IGFBP was therefore systematically explored (Figs 5 and 6). SMCs were seeded at three different densities and grown in 10% FCS until sparse, subconfluent, and confluent conditions were attained (cell counts at the time of harvest were 6.2, 9.8, and 11.2x105 cells per square centimeter, respectively). As shown in Fig 5, basal levels as well as the IGF-I-dependent increase of the 38-to 45 -kD IGFBP (IGFBP-3) were barely detectable in sparsely plated cells, whereas confluent cells showed a clear concentration-dependent increase in this protein. Cell confluence had no effect on IGFBP-3 mRNA abundance of basal or IGF-I-treated SMCs (Fig  6) . Basal levels of the 24-kD IGFBP were unaffected by confluence; the IGF-I-mediated decrease, however, was clearly cell-density dependent (Fig 5) . In marked (Fig 6) . Finally, the content of both the 30- * 0* a * 0 0 4 * * *"* *s* * 4 cyclophilin sence of IGF-I is greater in the confluent than in the sparsely plated cells). IGF-I promotes a rapid degradation of IGFBP-4, particularly in medium from confluent SMCs. The proteolysis of IGFBP-4 in the presence of IGF-I was absent at 4°C, slightly greater at 20°C, and maximal at 37°C (data not shown) and completely abrogated by EDTA and by high concentrations of benzamidine. Phenylmethylsulfonyl fluoride (PMSF) and the plasmin inhibitor bdellin were relatively ineffective (Fig 8) .
Proteolysis of IGFBP-4 was further explored by incubating purified human 1251IIGFBP-4 with SMC-conditioned medium (Fig 9) . The labeled binding protein was stable in the absence of conditioned medium for 6 hours, even when incubated with 50 ng/mL IGF-I.
Conditioned medium from confluent SMCs contained proteolytic activity, which generated fragments of --18 and 14 kD. Generation of these products was markedly enhanced by the addition of IGF-I. Proteolysis was inhibited by EDTA and, to a lesser degree, by PMSF. There was no enhancement of basal proteolysis by addition of the IGF-I analogues long R3 or des (1-3) IGF-I. Finally, both basal proteolysis and IGF-J-stimulated proteolysis were less marked when the 25I-IGFBP-4 was incubated with conditioned medium from sparsely plated SMCs.
These data suggest that IGFBP-4 is inactivated by a cation-dependent protease in the presence of IGF-I or IGF-II. To examine whether this process affects the integrity of IGF-I itself, 1251IIGF-I was incubated with 
Discussion
IGF-I is an attractive candidate to serve as one of the significant mediators of the response to vascular injury. IGF-I is the most abundant circulating polypeptide growth factor, and it is also elaborated by SMCs within the vessel wall, where it may exert its effects in a paracrine fashion.12'13 IGF-I is additive in its effects with both PDGF and FGF, widely regarded as powerful mitogens for arterial SMCs. The abundance of IGF-I may ultimately be a major determinant of the magnitude of the mitogenic response after injury.12,13,4243 The biologic activity of IGF-I is determined in part by its association with IGF-binding proteins in the extracellu-IGF-l (ng/ml) lar space, which can modulate its interaction with the cell membrane receptor. The major form elaborated by vascular SMCs in vitro is a 24-kD IGFBP, thought to be IGFBP-4, which has been shown to inhibit IGF-I action in a variety of systems.44 It is not known whether IGFBP-4 is also inhibitory in vivo.
In the present study, we present evidence that IGFs regulate the 24-kD IGFBP-4 in rat aortic SMCs by promoting its degradation in a confluence-dependent manner. In addition, the elaboration and IGF stimulation of 38-to 42-kD IGFBP-3 in these cells is also observed more readily in highly confluent SMCs, without concomitant changes in IGFBP-3 mRNA abundance, suggesting that this binding protein may production and degradation is unique and suggests that the regulation of IGF-I bioavailability may be under far more subtle and complex controls than previously thought. Of note is that abundance of the 30-kD IGFBP decreased as a function of cell confluence, as did IGFBP-2 mRNA levels. These data further emphasize the concept that cell density plays a major role in the regulation of IGFBP content of SMC-conditioned medium and may be critical in determining IGF-I action. There are several examples of genes whose expression is altered by cell confluence in vascular SMCs. Densityarrested vascular SMCs show increased expression of extracellular matrix mRNAs for type III collagen and fibronectin. 50 The vascular smooth muscle a-actin gene is maximally induced in postconfluent mouse BC3H1 cells, a line derived from cerebrovascular SMCs.51 Indeed, Min et a152 have identified a "cell density responsive element" between positions -1074 and -372 of the a-actin 5' flanking region. Therefore, the expression of both differentiated genes and of proteins regulating cell attachment and growth is confluence dependent in vascular SMCs.
Recently, Martin et a153 reported that IGF-I can evoke release of preformed IGFBP-3 present on the cell surface of neonatal skin fibroblasts and that this effect does not require interaction of IGF-I with its specific receptor. An increase of IGFBP-3 in conditioned medium was also observed after treatment of cells with heparin, suggesting that IGFBP-3 may be attached to glycosaminoglycans on the cell surface. We were unable to demonstrate a similar effect of heparin on IGFBP-3 release in vascular SMCs (data not shown). The mechanism for IGF-induced increase of IGFBP-3 is at this point unclear, although in all likelihood it is due to posttranslational events, because no induction of IGFBP-3 mRNA was observed.
Finally, our data clearly demonstrate that, even after prolonged incubation, the proteolytic activity in conditioned medium from confluent cultures does not affect the integrity of IGF-I itself. This strengthens the contention that the cation-dependent protease is involved in increasing the availability of free IGF-I for association with its cell membrane receptor or other binding proteins. However, bioactivity of IGF-I released from its binding site on IGFBP-4 needs to be formally tested. We have previously reported that IGF-L gene expression increases in the rat aorta after balloon injury.12,13,42 The biologic effects of IGF-I are likely to be dependent not only on the abundance of the growth factor itself but also on the presence of IGFBPs in the extracellular environment and on the activation of specific proteases that ultimately release IGF-I for interaction with vascular SMCs.
